A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors

Trial Profile

A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Trametinib (Primary)
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2013 Actual initiation date changed from Sep 2011 to Sep 2012 as reported by ClinicalTrials.gov.
    • 31 May 2013 Actual initiation date changed from Sep 2012 to Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top